Journal of Oncology / 2010 / Article / Tab 1

Review Article

Antiangiogenic Therapy and Mechanisms of Tumor Resistance in Malignant Glioma

Table 1

Anti-angiogenic agents trialled in high-grade glioma and their respective targets.

Antibody TherapiesMajor Molecular Targets
BevacizumabFree VEGF-A
IMC-3G3PDGFR alpha
RamucirumabVEGFR-2
NimotuzumabEGFR
AMG-102Hepatocyte Growth Factor
VEGF-trapDecoy receptor for VEGF

Tyrosine Kinase Inhibitors
CediranibVEGFR/PDGFR/c-Kit
SorafenibVEGFR/PDGFR/c-Kit/Raf
SunitinibVEGFR/PDGFR
AE788EGFR/VEGFR
ErlotinibEGFR
ImatinibPDGFR/Bcr-abl/c-Kit
DasatanibSrc kinases

Signal Pathway Inhibitors
EnzastaurinProtein Kinase C
Rapamycin/TemsirolimusmTOR
TipifarnibRas

Other Agents
Thalidomide/LenalidomideNO/TNF alpha/IL-6
CelecoxibEndostatin
CilengitideIntegrins 𝛼 𝑣 𝛽 3 and 𝛼 𝑣 𝛽 5
2-methoxyestradiolHIF1 𝛼
PrinomastatMMPs 2,9,13 and 14
SAHA(Vorinostat)Histone deacetylase